2023 CE
First approval of a CRISPR-based treatment
Genética y biotecnología · Terapias génicas · CRISPR · Acceso sanitario
Regulators authorised a CRISPR-based treatment for sickle-cell disease in 2023, editing a patient’s own cells. The authorisation applies to specific indications and health systems; it does not make genome editing accessible, appropriate, or equivalent for every disease.
Precision, calendar, and review
- Start
- year · no uncertainty qualifier in this record
- Calendar and convention
- Historical-era years; the source calendar is not identified. No conversion of days is assumed.
- Year zero
- The scale goes from 1 BCE to 1 CE without year zero. Changing era names changes labels only.
- Documentary review
- Date not recorded
Reading the date: point event.
Sources
- www.fda.gov (opens in a new tab)
Source provenance and scope
- Publication date
- Not identified in metadata; document review pending
- Bibliographic date checked
- 2026-09-23
The correspondence between this reference and individual claims has not yet been itemized.
This record is an editorial synthesis. Consult the sources to check claims and their limits. Chronological relationships alone do not establish causation.